tbuckley/cabot-search huggingface dataset:
A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL)
Authors: Alessandra Tucci, Gerardo Musuraca, Federica Cavallo, Vittorio Ruggero Zilioli, Manuela Zanni, Sabrina Pelliccia, Donato Mannina, Mariagrazia Michieli, Daniele Vallisa, Monica Tani, Francesco Merli, Francesca Re, Luigi Marcheselli, Giulia Campostrini, Chiara Pagani, Daniele Grimaldi, Eliana Valentina Liardo, Alessandro Re, M. Christina Cox, Giuseppe Rossi
Journal: Blood (2021)
Takotsubo Syndrome Versus Myocardial Infarction: what is the role of Echocardiography?
Authors: Raquel Menezes Fernandes, Hugo Costa, Teresa Mota, João Bispo, Pedro Azevedo, Dina Bento, Nuno Marques
Journal: Clinical Cardiology and Cardiovascular Interventions (2019)

Reversible left ventricle dysfunction is a key feature of Takotsubo syndrome (TTS), but in the acute phase it can mimic an acute coronary syndrome, making this differentiation a significant challenge. Echocardiography is widely used in the early evaluation of these patients, and advanced imaging tools have highlighted the differences between both syndromes. The symmetrical pattern of left ventricular dysfunction, extending beyond the territory of a single coronary artery, associated with a less severe diastolic dysfunction, right ventricle involvement and a typical complete recovery of wall-motion abnormalities points towards the diagnosis of TTS. Despite all the imaging advances made so far, evaluation of coronary anatomy remains mandatory in these patients.
Targeting the Oncogenic Functions of an RNA-Binding Protein Involved in Hematologic Malignancies
Authors: Sean M Post, Prerna Malaney, Lauren Chan, Xiaorui Zhang, Todd Link, Eun Cho, Juan Cerda, Marisa J Aitken, Mary Sobieski, Reid Powell, Nghi Nguyen, Clifford Stephan, Kevin Dalby
Journal: Blood (2021)
Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence
Authors: Torsten Dahlen, Camille Kockerols, Germano Ferreira, Peter E. Westerweel, Jiří Mayer, Tarek Sahmoud, David Wormser, Lillian Yau, Daniela Žácková
Journal: Blood (2021)
Abstract PO-116: Deletion of <i>Arginase 1</i> in myeloid cells alters the pancreatic cancer microenvironment
Authors: Rosa E. Menjivar, Zeribe Nwosu, Wenting Du, Katelyn Donahue, Carlos Espinoza, Ashley Velez-Delgado, Kristee Brown, Wei Yan, Christopher Halbrook, Yaqing Zhang, Costas Lyssiotis, Marina Pasca di Magliano
Journal: Cancer Research (2021)

Abstract Pancreatic ductal adenocarcinoma (PDA) is a deadly disease with a 5-year survival of only 10%. PDA is characterized by an abundant fibroinflammatory stroma that includes abundant fibroblasts and immune cells, mainly myeloid cells. Infiltrating myeloid cells express high levels of Arginase 1 (Arg1), an enzyme that metabolizes L-arginine. Conversely, CD8+ T cells are scarce in PDA, and when present have an overwhelmingly exhausted phenotype. Whether myeloid cell Arginase is a key driver of immune suppression in pancreatic cancer is unknown. Here, we tested the hypothesis that myeloid cells in the tumor microenvironment mediate immune suppression in PDA through expression of Arg1. To test this hypothesis, we used a combination of genetically engineered pancreatic cancer mouse models and pharmacological approaches. Using a FlpO- and Cre-based dual recombinase system, we have generated a mouse model that develops pancreatic cancer spontaneously because of oncogenic Kras expression in the epithelium, while at the same time lacking Arg1 expression in the myeloid cell compartment (Ptf1a-FlpO/+;KrasFrt-STOP-Frt-G12D/+;LysMCre;Arg1f/f). To complement the genetic model and inhibit the function of Arginase systemically, we used an Arginase inhibitor (CB-1158, Incyte, Inc.) alone and in combination with an immune checkpoint blockade (anti-PD1). Using these multiple approaches, we observed decrease progression to invasive disease in the genetic model, and sensitization to immune checkpoint treatment in the transplantation model. In both settings, changes in tumor growth were accompanied by an increase in CD8+ T cell infiltration and activation. These changes support the notion that myeloid Arg1 is mediator of immune suppression in PDA, and a potential therapeutic target. Citation Format: Rosa E. Menjivar, Zeribe Nwosu, Wenting Du, Katelyn Donahue, Carlos Espinoza, Ashley Velez-Delgado, Kristee Brown, Wei Yan, Christopher Halbrook, Yaqing Zhang, Costas Lyssiotis, Marina Pasca di Magliano. Deletion of Arginase 1 in myeloid cells alters the pancreatic cancer microenvironment [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-116.
Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis
Authors: Pamela Allen, Qing C Chen, Xinyan Lu, Kaitlyn O'Shea, Joan Chmiel, Madina Sukhanova, Liron Barnea Slonim, Hatice Savas, Eric Mou, Barbara Pro, Andrew M. Evens, Brett Alan Palmer, Ranjana Advani, Leo I. Gordon, Jane N. Winter
Journal: Blood (2021)
The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis
Authors: Tiziano Barbui, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Greta Carioli, Alessandro Rambaldi, Maria Chiara Finazzi, Marta Bellini, Elisa Rumi, Daniele Vanni, Oscar Borsani, Francesco Passamonti, Barbara Mora, Marco Brociner, Alessandro Vannucchi, Paola Guglielmelli, Chiara Paoli, Alberto Alvarez-Larran, Ana Triguero, Marta Garrote, Helna Pettersson, Björn Andréasson
Journal: Blood (2021)
B Cell Transcriptional Coactivator <i>POU2AF1</i> (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication
Authors: Zuzana Chyra, Mehmet K. Samur, Anil Aktas-Samur, Yao Yao, Sanika Derebail, Tommaso Perini, Yan Xu, Eugenio Morelli, Sophia Adamia, Woojun D Park, Lin Charles, Ryosuke Shirasaki, Masood A. Shammas, Constantine S. Mitsiades, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi
Journal: Blood (2021)
Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia
Authors: Kenshi Suzuki, Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu
Journal: Blood (2021)
ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)
Authors: Amro Elshoury, Han Yu, Wenyan Ji, James E. Thompson, Elizabeth A. Griffiths, Amanda Przespolewski, Steven Daniel Green, Pamela J. Sung, Sheeba baAqeel, Hassan Awada, Eunice S. Wang, Peter A. Kouides
Journal: Blood (2021)
Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
Authors: Cristina Bagacean, Rémi Letestu, Chadi Al Nawakil, Ségolène Brichler, Vincent Lévy, Nanthara Sritharan, Alain Delmer, Caroline Dartigeas, Véronique Leblond, Damien Roos-Weil, Marie C Béné, Aline Clavert, Driss Chaoui, Philippe Genet, Romain Guieze, Kamel Laribi, Yamina Touileb, Bernard Drenou, Lise Willems, Cécile Tomowiak, Fatiha Merabet, Christian Puppink, Hugo Legendre, Xavier Troussard, Stéphanie Malartre, Florence Cymbalista, Anne-Sophie Michallet
Journal: Blood (2021)
Abstract 10639: Abbreviated Cardiac Magnetic Resonance Imaging versus Echocardiography for Interval Assessment of Systolic Function in Duchenne Muscular Dystrophy: Patient Satisfaction, Clinical Utility and Image Quality
Authors: Hamsika Chandrasekar, Beth D Kaufman, Shreyas Vasanawala, Meaghan Beattie, Ali B Syed, Shiraz A Maskatia
Journal: Circulation (2021)

Introduction: Interval assessment of systolic function in patients with Duchenne Muscular Dystrophy (DMD) is challenging by echocardiography (echo). Cardiac magnetic resonance imaging (CMR) has been limited due to study duration and patient experience. We developed an abbreviated CMR (aCMR) protocol which consisted only of cine acquisitions in the short axis, 4 chamber and vertical long axis planes, and compared it to echo in regard to: exam duration, patient satisfaction, clinical utility and image quality scores. Methods: DMD patients were recruited prospectively to undergo simultaneous echo and aCMR. Exclusion criteria included need for continuous positive pressure ventilation (PPV) and inability to lay supine ≥ 30 minutes. Subjects completed a patient satisfaction survey (PSS) comparing modalities. The clinical cardiologist completed a survey (CUS) assessing the clinical utility of each modality. A blinded expert reviewer completed an image quality survey (GQAS) for each modality. Results were compared using the Wilcoxon signed-rank test and Spearman correlation. Results: 19 DMD patients participated. PSS scores and exam duration were equivalent between modalities, while CUS and GQAS scores favored aCMR. ACMR scored particularly higher than echo in RV visualization and judgement of atrial size. Older age had a statistically significant negative correlation with echo GQAS and CUS scores, as well as aCMR PSS scores. Nighttime PPV requirement and non-ambulatory status were associated with worse echo CUS scores. Poor image quality precluding quantification existed in 4 (21%) echo and 0 aCMR studies. Conclusions: The aCMR protocol resulted in improved clinical utility and quality scores relative to echocardiography, without detriment in patient satisfaction or exam duration. For DMD patients known to have challenging echo acoustic windows, aCMR should be considered in lieu of echocardiography for interval assessment of systolic function.
Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study
Authors: Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Hervé Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Didier Blaise, Steven G.E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda
Journal: Blood (2021)
Abstract PR-014: Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1
Authors: Marie C. Hasselluhn, Amanda R. Decker, Alvaro Curiel Garcia, Carlo Maurer, Dafydd Thomas, Kenneth P. Olive
Journal: Cancer Research (2021)

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is characterized by an extremely heterogeneous tumor microenvironment (TME) paired with a sparse and compromised vascular network. These features of the TME shape drug responses and contributes to PDAC’s distinctive chemotherapeutic resistance. Prior work demonstrated that inhibition of the Hedgehog (Hh) signaling using Smoothened (Smo) inhibitors relieved some of the local angiogenic suppression. However, the precise mechanisms through which the Hh pathway regulates angiogenesis has remained elusive. Subsequent studies evaluating different timepoints yielded conflicting data on the role of Hedgehog signaling in angiogenesis. In order to replicate the heterogeneity and spatial patterning of cells in pancreatic tumors, we developed a novel tumor explant system for short-term cultures of both murine and human PDAC. Briefly, we cultured intact 300 μm slices of PDAC tissues in a modified gelatin platform system with a novel culture medium informed by the metabolic composition of PDAC tumor interstitial fluid. This system replicates some of the nutrient/waste gradient of PDAC and enables tumors to be culture up to one week with good representation of multiple cell types. Studies in explants were complemented by work in the KPC genetically engineered model of PDAC. Comparison of short versus long-term Smo inhibition in KPC mouse pancreatic tumors revealed a robust increase in vessel density in short-term treatment, which is lost at later timepoints. Studies in murine and human PDAC explants employing different Smo inhibitors demonstrated increased endothelial tip cell formation upon two days of treatment, resulting in increased vessel density after four days. Computational analyses of human PDAC single cell RNAseq data identified candidate cellular subsets potentially involved in the signaling cascade. RNAseq of pre- and on-treatment tumor samples from KPC mice identified Wif1 as a candidate Hh target gene that effected these programs. Mechanistic studies in tumor explants reveal a complex, multi-step mechanism involving multiple cell types that led to suppression of angiogenesis in PDAC. These studies demonstrate how the tumor explant platform can elucidate complex intercellular signaling cascades and provide a candidate mechanism for the Hh-mediated suppression of angiogenesis in PDAC. Citation Format: Marie C. Hasselluhn, Amanda R. Decker, Alvaro Curiel Garcia, Carlo Maurer, Dafydd Thomas, Kenneth P. Olive. Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1 [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PR-014.
ALKBH5 Modulates Hematopoietic Stem and Progenitor Cell Energy Metabolism through m 6a Modification-Mediated RNA Stability
Authors: Yimeng Gao, Joshua T Zimmer, Radovan Vasic, Chengyang Liu, Rana Gbyli, Shu-Jian Zheng, Amisha Patel, Wei LIU, Raman Nelakanti, Yuanbin Song, Giulia Biancon, Andrew Xiao, Sarah Slavoff, Matthew D Simon, Richard Flavell, Toma Tebaldi, Hua-Bing Li, Stephanie Halene
Journal: Blood (2021)
Chromothripsis followed by circular recombination drives oncogene amplification in human cancer
Authors: Carolina Rosswog, Christoph Bartenhagen, Anne Welte, Yvonne Kahlert, Nadine Hemstedt, Witali Lorenz, Maria Cartolano, Sandra Ackermann, Sven Perner, Wenzel Vogel, Janine Altmüller, Peter Nürnberg, Falk Hertwig, Gudrun Göhring, Esther Lilienweiss, Adrian M. Stütz, Jan O. Korbel, Roman K. Thomas, Martin Peifer, Matthias Fischer
Journal: Nature Genetics (2021)
Abstract 3731: Marked Reduction in Cardiovascular Events with Pravastatin in Hypercholesterolemic Patients with Mild or Moderate Chronic Kidney Disease
Authors: Haruo Nakamura
Journal: Circulation (2007)

Background: Chronic kidney disease (CKD) has been identified as a potent risk factor for cardiovascular disease. In persons with CKD, a reduction in the incidence of cardiovascular events was obser...
Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study
Authors: Zhuoer Xie, Meredith C. Hyun, Rami S. Komrokji, Amer M. Zeidan, Yazan F. Madanat, Joshua F. Zeidner, Catherine C. Coombs, Elizabeth A. Griffiths, Catherine Lai, Ashwin Kishtagari, James M. Foran, Talha Badar, Cecilia Arana Yi, Pinkal Desai, Lionel Ades, Afaf Osman, Justin Taylor, H. Joachim Deeg, Andrew M. Brunner, Hetty E. Carraway, Najla Al Ali, Jan Philipp Bewersdorf, Thomas Prebet, Abhay Singh, Charlton Tsai, Namrata Chandhok, Deborah Soong, Mrinal M. Patnaik, Michael R. Savona, Aref Al-Kali
Journal: Blood (2021)
Higher Grade Cytokine Release Syndrome Is a Predictive Factor for Gvhd in Haploidentical Stem Cell Transplantation with Peripheral Blood Cell
Authors: Benjamin Bouchacourt, Valerio Maisano, Ana Benzaquen, Angela Granata, Sabine Furst, Faezeh Legrand, Thomas Pagliardini, Sandrine Loron, Samia Harbi, Pierre-Jean Weiller, Marie-Joelle Mozziconacci, Claude Lemarie, Boris Calmels, Christian Chabannon, Didier Blaise, Raynier Devillier
Journal: Blood (2021)
Evaluation and Management of Amenorrhea
Authors: Sarah Pitts, Amy D. DiVasta, Catherine M. Gordon
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT
Authors: Noriharu Nakagawa, Ken Ishiyama, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda, Masahide Yamamoto, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki
Journal: Blood (2021)
Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models
Authors: Lila Rouland, Eric Duplan, Lígia Ramos dos Santos, Aurore Bernardin, Karen S. Katula, Guidalberto Manfioletti, Ahmed Idbaih, Frédéric Checler, Cristine Alves da Costa
Journal: Theranostics (2021)

à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Abstract 13153: Vascular Function and the Gut Microbiome in Liver Transplant Recipients
Authors: Moriah Carper, Domenico Chavez, Natalie Bohmke, Linsey Martin, Chandra Bhati, Susan Wolver, Mohammad Siddiqui, Danielle L Kirkman
Journal: Circulation (2021)

Introduction: Cardiovascular disease (CVD) risk is elevated in liver transplant (LT) patients. The underlying physiological mechanisms associated with LT related CVD are not yet fully understood. High levels of the gut microbiome metabolite trimethylamine N-oxide (TMAO) may contribute to an increased risk of atherosclerosis. The purpose of this study is to investigate if high circulating levels of TMAO contribute to vascular dysfunction in LT recipients. Hypothesis: We hypothesized that vascular dysfunction, including measures of conduit artery endothelial function, central systolic blood pressure and carotid intima media thickness (cIMT), would be correlated with higher TMAO levels. Methods: We enrolled 12 LT recipients (6 male; 6 female; Mean±SD: Age 58.75±8.45 yrs). Conduit artery endothelial function was measured via flow-mediated dilation with duplex ultrasound. Central aortic pressure waves were synthesized from radial artery waveforms acquired by applanation tonometry and the use of a generalized transfer function. Mean cIMT of the near and far wall was assessed via B mode ultrasound. Blood samples were analyzed for plasma TMAO by nuclear magnetic resonance spectroscopy. Results: As shown in Figure 1, conduit artery endothelial function (Mean±SD: 4.11±2.82%) was negatively associated with TMAO (10.94±9.65 μM; r = -0.87, p &lt;0.001). There was no significant relationship between TMAO and central aortic pressure (131±17mmHg; r = 0.36, p =0.3) or cIMT (0.68±0.10mm; r = -0.08, p =0.8). Conclusions: Our results showed that LT recipients with higher levels of plasma TMAO had worse conduit artery endothelial function. Endothelial dysfunction is a well-established precursor to the development of atherosclerosis. Therefore, therapeutic strategies aimed at improving the health of the gut microbiome and subsequently reducing the levels of TMAO hold promise for preventing atherosclerosis in LT patients and should be investigated in future trials.
Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations
Authors: Sravya Tumuluru, James Godfrey, Jovian Yu, Alan Cooper, Xiufen Chen, Gerben Duns, Sonali M. Smith, Christian Steidl, Justin Kline
Journal: Blood (2021)
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial
Authors: Katja Weisel, Meletios A. Dimopoulos, Jesús San-Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord-Bessen, David Yao, Christine Yip, Mike Greenwood, Jackson Tang, Michele Cavo
Journal: Blood (2021)
Abstract 13836: Unbiased Deep Learning Approach Utilizing Longitudinal Data in Assessing All-Cause Mortality in Patients With a <i>De Novo</i> or Worsened Heart Failure
Authors: Robert Herman, Marc Vanderheyden, Boris Vavrik, Monika Beles, Timotej Palus, Zuzana Kepesiova, Marc Goethals, Sofie Verstreken, Riet Dierckx, Ward Heggermont, Jozef Bartunek
Journal: Circulation (2021)

Introduction: Heart failure (HF) is a heterogenous syndrome with complex pathophysiology. Biomarkers and clinical risk scores often fail to capture modifications in the treatment continuity and provide suboptimal patient-level precision in the prognostic stratification. Electronic patient records provide necessary granularity yielding opportunities to develop new artificial intelligence (AI) based strategies for comprehensive prognostic re-stratification. Hypothesis: We assessed the hypothesis that, utilizing longitudinal patient data in an AI approach, yields superior performance predicting all-cause mortality in a cohort of patients hospitalized with a de novo or worsened HF, compared to single observational time point predictions. Methods: In a cohort of 2449 HF patients hospitalized between 2011-2017, we utilized 151 451 patient exams from 422 parameters. Features included clinical phenotyping, medication, ECG, laboratory, echocardiography, catheterization data or percutaneous and surgical interventions gathered on a routine clinical basis reflecting standard of care as captured in individual electronic records. AI models were developed, and their performance on the validation set was compared to industry standard clinical scores. Results: AI models yielded performance ranging from 0.83 to 0.89 AUC on the outcome-balanced validation set in predicting all-cause mortality at 30-, 90-, 180-, 360- and 720-day time-limits. The primary endpoint, 1-year mortality prediction model, recorded 0.85 AUC on the validation set compared to 0.7 AUC (Seattle HF model) and 0.73 AUC (MAGGIC HF Score) respectively. Conclusions: Our findings present a novel, patient-level, AI-based risk prediction approach of all-cause mortality in heart failure utilizing all historical data available in electronic health records. This suggests the potential of AI based predictive models in a point-of-care approach to guide clinical risk stratification.
Global Coagulation Potentials and Breakthrough Bleeds in Emicizumab-Treated Hemophilia a Patients Were Similar to Mild Hemophilia a Patients
Authors: Yuto Nakajima, Kuniyoshi Mizumachi, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami
Journal: Blood (2021)